Skyhawk Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2016-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.skyhawktx.com
Clinical Trials
2
Active:0
Completed:0
Trial Phases
2 Phases
Phase 1:1
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 2
1 (50.0%)Study of SKY-0515 for Safety, Efficacy, and Pharmacodynamics in Participants With Huntington's Disease
Phase 2
Recruiting
- Conditions
- Huntington DiseaseHuntingtons Disease
- Interventions
- Drug: SKY-0515 Placebo
- First Posted Date
- 2025-03-12
- Last Posted Date
- 2025-07-09
- Lead Sponsor
- Skyhawk Therapeutics, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT06873334
- Locations
- 🇦🇺
John Hunter Hospital, New Lambton Heights, New South Wales, Australia
🇦🇺Westmead Hospital, Westmead, New South Wales, Australia
🇦🇺The University of Queensland, Herston, Queensland, Australia
News
No news found